Go Pro
→ Major Buy Alert Issued for August 31st (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$30.57
+3.1%		$26.32
$19.69
▼
$30.96
$5.11B0.811.81 million shs1.52 million shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$31.35
+10.9%		$31.67
$17.00
▼
$35.83
$1.39B1.36403,898 shs961,652 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$60.90
+6.7%		$53.32
$44.12
▼
$78.48
$5.52B1.741.56 million shs2.08 million shs
Grifols, S.A. stock logo
GRFS
Grifols
$8.09
+1.3%		$7.61
$6.96
▼
$10.23
$5.44B0.66532,175 shs375,056 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
+3.10%+1.29%+23.07%+44.27%+20.73%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
+10.93%+4.50%-1.20%+14.12%+62.02%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
+6.69%+14.97%+30.86%+13.77%+12.51%
Grifols, S.A. stock logo
GRFS
Grifols
+1.25%+4.39%+6.73%+0.50%-17.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$30.57
+3.1%		$26.32
$19.69
▼
$30.96
$5.11B0.811.81 million shs1.52 million shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$31.35
+10.9%		$31.67
$17.00
▼
$35.83
$1.39B1.36403,898 shs961,652 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$60.90
+6.7%		$53.32
$44.12
▼
$78.48
$5.52B1.741.56 million shs2.08 million shs
Grifols, S.A. stock logo
GRFS
Grifols
$8.09
+1.3%		$7.61
$6.96
▼
$10.23
$5.44B0.66532,175 shs375,056 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
+3.10%+1.29%+23.07%+44.27%+20.73%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
+10.93%+4.50%-1.20%+14.12%+62.02%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
+6.69%+14.97%+30.86%+13.77%+12.51%
Grifols, S.A. stock logo
GRFS
Grifols
+1.25%+4.39%+6.73%+0.50%-17.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.78
Moderate Buy$34.3612.40% Upside
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
2.70
Moderate Buy$44.8643.08% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.61
Moderate Buy$68.0611.75% Upside
Grifols, S.A. stock logo
GRFS
Grifols
1.67
Reduce$10.0023.61% Upside

Current Analyst Ratings Breakdown

Latest AVBP, CRSP, GRFS, and ACAD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$37.00 ➝ $38.00
8/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$27.00 ➝ $28.00
8/25/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/25/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$39.00 ➝ $40.00
8/25/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$80.00
8/17/2026
Grifols, S.A. stock logo
GRFS
Grifols
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
8/17/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $49.00
8/17/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$44.00 ➝ $47.00
8/13/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$43.00 ➝ $40.00
8/13/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
8/13/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$42.00
(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.07B4.92$0.91 per share33.42$7.58 per share4.03
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A$7.44 per shareN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$3.51M1,677.61N/AN/A$18.06 per share3.37
Grifols, S.A. stock logo
GRFS
Grifols
$7.42B0.74$1.43 per share5.64$13.63 per share0.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.2213.7731.1923.3533.42%9.03%6.79%11/4/2026 (Estimated)
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$166.31M-$3.62N/AN/AN/AN/A-50.26%-46.66%N/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$4.76N/AN/AN/A-3,368.72%-24.39%-18.25%11/9/2026 (Estimated)
Grifols, S.A. stock logo
GRFS
Grifols
$454.82M$0.1942.586.180.295.54%6.21%2.39%11/10/2026 (Estimated)

Latest AVBP, CRSP, GRFS, and ACAD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.9873-$1.05-$0.0627-$1.05N/AN/A
8/4/2026Q2 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.0682$0.18+$0.1119$0.18$296.55 million$308.00 million
8/3/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.19-$0.94+$0.25-$0.94$7.45 million$10.18 million
6/30/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A-$0.94N/A-$0.94N/A$10.18 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Grifols, S.A. stock logo
GRFS
Grifols
$0.080.99%N/A42.11%N/A

Latest AVBP, CRSP, GRFS, and ACAD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/19/2026
Grifols, S.A. stock logo
GRFS
Grifols
special$0.09457/2/20267/2/20267/9/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.39
3.30
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
14.16
14.16
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.34
17.85
17.85
Grifols, S.A. stock logo
GRFS
Grifols
1.10
2.37
0.81

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Grifols, S.A. stock logo
GRFS
Grifols
N/A

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
8.58%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
5.20%
Grifols, S.A. stock logo
GRFS
Grifols
0.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510172.31 million127.16 millionOptionable
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
4049.31 million45.08 millionN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46096.69 million91.67 millionOptionable
Grifols, S.A. stock logo
GRFS
Grifols
25,247680.58 million679.28 millionOptionable

Recent News About These Companies

Grifols (NASDAQ:GRFS) Shares Cross Above Two Hundred Day Moving Average - What's Next?
August 25 at 2:00 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30981141
Grifols (NASDAQ:GRFS) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?
August 25 at 1:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-grifols-nasdaq-grfs-stock-price-crosses-above-200-day-moving-average-time-to-sell-2026-08-25/
Short Interest in Grifols, S.A. (NASDAQ:GRFS) Drops By 45.5%
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-grifols-sa-nasdaqgrfs-drops-by-455-2026-08-17/
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/grifols-announces-last-patient-last-visit-in-sparta-its-phase-3-outcomes-study-of-prolastin--c-in-patients-with-emphysema-due-to-alpha-1-antitrypsin-deficiency-1036435305
Grifols Announces Completion of SPARTA Phase 3 Trial Follow-Up for Prolastin-C in Alpha-1 Emphysema
August 10, 2026  |  quiverquant.comQ
Janus Henderson Group PLC Has $26.35 Million Stock Holdings in Grifols, S.A. $GRFS
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-janus-henderson-group-plc-has-2635-million-stock-holdings-in-grifols-sa-grfs-2026-08-04/
Sei Investments Co. Sells 138,197 Shares of Grifols, S.A. $GRFS
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sei-investments-co-sells-138197-shares-of-grifols-sa-grfs-2026-08-02/
Grifols Reshapes Board and Committee Leadership After Director Resignation
July 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/grifols-reshapes-board-and-committee-leadership-after-director-resignation?utm_source=marketbeat.com&utm_medium=referral
Grifols (GRFS) Q2 2026 Earnings Call Transcript
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/grifols-grfs-q2-2026-earnings-011235282.html
Grifols (NASDAQ:GRFS) Sees Large Volume Increase - Here's What Happened
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/grifols-nasdaqgrfs-sees-large-volume-increase-heres-what-happened-2026-07-29/
Grifols Half-Year 2026 Results: Profit Jumps as Refinancing Bolsters Balance Sheet
July 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/grifols-half-year-2026-results-profit-jumps-as-refinancing-bolsters-balance-sheet?utm_source=marketbeat.com&utm_medium=referral
Grifols, S.A. 2026 Q2 - Results - Earnings Call Presentation
July 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4926500-grifols-s-a-2026-q2-results-earnings-call-presentation
Grifols Q2 Earnings Call Highlights
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/grifols-q2-earnings-call-highlights-2026-07-28/
Grifols, S.A. (GRFS) Stock Rises on Q2 2026 Earnings
July 28, 2026  |  quiverquant.comQ
Grifols SA Q2 2026 earnings preview
July 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/grifols-sa-q2-2026-earnings-preview/ar-AA28OcoD
Grifols, S.A. $GRFS Shares Sold by Whitebox Advisors LLC
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-grifols-sa-grfs-shares-sold-by-whitebox-advisors-llc-2026-07-27/
Flat Footed LLC Buys 287,867 Shares of Grifols, S.A. $GRFS
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-flat-footed-llc-buys-287867-shares-of-grifols-sa-grfs-2026-07-27/
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
July 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/16/3328383/0/en/grifols-doses-first-patients-in-two-phase-3-trials-to-expand-indications-of-its-flagship-immunoglobulins.html
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
July 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4919718-grifols-operational-recovery-and-balance-sheet-improvement-support-a-return-to-buy-rating-upgrade
Grifols Reshapes Board and ESG Committee Following Director Resignation
June 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/grifols-reshapes-board-and-esg-committee-following-director-resignation?utm_source=marketbeat.com&utm_medium=referral
Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment
June 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/grifols-grfs-launches-fesilty-u-165231770.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$30.57 +0.92 (+3.10%)
Closing price 08/25/2026 04:00 PM Eastern
Extended Trading
$30.79 +0.22 (+0.71%)
As of 08:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ArriVent BioPharma stock logo

ArriVent BioPharma NASDAQ:AVBP

$31.35 +3.09 (+10.93%)
Closing price 08/25/2026 04:00 PM Eastern
Extended Trading
$31.90 +0.55 (+1.75%)
As of 08:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$60.90 +3.82 (+6.69%)
Closing price 08/25/2026 04:00 PM Eastern
Extended Trading
$60.58 -0.32 (-0.53%)
As of 08:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Grifols stock logo

Grifols NASDAQ:GRFS

$8.09 +0.10 (+1.25%)
Closing price 08/25/2026 04:00 PM Eastern
Extended Trading
$8.09 0.00 (0.00%)
As of 07:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas